Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented NSCLC, including squamous cell carcinoma, adenocarcinoma (including bronchoalveolar cell), and large cell anaplastic carcinoma (including giant and clear cell carcinomas).~* Eligible Disease Stages: Inoperable IIIA and Selected IIIB~* Local radiation oncologist must approve patient eligibility prior to entry on study.~* Patients must have measurable disease.~* Prior Therapy:~  * ≥ 2 weeks since formal exploratory thoracotomy.~ * No prior chemotherapy or radiation therapy for NSCLC.~* ECOG performance status 0-1~* Required Initial Laboratory Values (must be submitted within 16 days prior to registration):~  * Granulocytes ≥ 1,500/µl~ * Platelets ≥ 100,000/µl~ * Calculated Creatinine Clearance ≥ 20 cc/min~ * Bilirubin \< 1.5 mg/dl~ * AST (SGOT) \< 2 x ULN~ * INR \> 0.8 \< 1.2\* \*Values apply exclusively to patients not being treated with warfarin. Values for patients being treating with warfarin should fall within the following therapeutic range: \> 2.0 \< 3.0.~Exclusion Criteria:~* Currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.~* Pregnant or nursing because of significant risk to the fetus/infant.~* Age \<18 years.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* No HIV-positive patients receiving combination anti-retroviral therapy. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy~* One-second forced expiratory volume (FEV1) \<50% or hemoglobin-corrected carbon monoxide diffusion capacity (DLCO) \<50% of predicted, as measured within 21 days of study entry~* Symptoms of esophageal dysfunction (dysphagia, odynophagia, or inability to swallow solid food) within 4 weeks prior to study randomization. Patients must not require prophylactic placement of percutaneous enterogastrostomy (PEG) tube or other non-oral nutritional supplement methods~* Weight loss of \> 10% in the past 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (first 12 eligible patients) (Type: OTHER): Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.
- Cohort 2 (remaining patients) (Type: EXPERIMENTAL): Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).